Micardis®

Dyslipidemia

Stanford UniversityN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

21 Active assets in the Dyslipidemia cohort.

Asset / Sponsor	Phase	Rating
Lipitor Johns Hopkins University	Phase 4	A
Rosuvastatin Korea University Anam Hospital	Phase 4	A
Metformin RenJi Hospital	Phase 4	BBB
SIMVASTATIN Eli Lilly and Company	Phase 4	BBB
Lipitor National Institute of Kidney Disease and Urology (NIKDU)	Phase 4	BBB

View all 50 →

Same molecule, other indications

Micardis® is also rated in:

hypertensive disorderDormant

BB

Indicative ·

71 / 100

abdominal obesity-metabolic syndromeDormant

BB

Indicative ·

70 / 100

schizoaffective disorderDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.